ALKERMES | ALKS - Interest Expense On Debt


ALKERMES reported $4.65M in Interest Expense on Debt for its fiscal quarter ending in December of 2024.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
ALKERMES USD 4.65M 1.35M Dec/2024
Amgen USD 685M 9M Sep/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.58M 100K Sep/2025
Bristol-Myers Squibb USD 480M 5M Sep/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 254M 6M Jun/2025
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
J&J USD 18M 290M Sep/2025
Merck USD 327M 22M Sep/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Otsuka Holdings JPY 1.34B 8.39B Sep/2025
Pfizer USD 652M 2M Sep/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Vertex Pharmaceuticals USD 3.3M 400K Sep/2025